Literature DB >> 6352139

Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

R E Bullingham, H J McQuay, R A Moore.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6352139     DOI： 10.2165/00003088-198308040-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  52 in total

1.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

Review 2.  Pentazocine: a review of its pharmacological properties, therapeutic efficacy and dependence liability.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1973       Impact factor: 9.546

3.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

4.  The anesthesia-sparing effect of pentazocine, meperidine, and morphine.

Authors:  J C Hoffman; C A DiFazio
Journal:  Arch Int Pharmacodyn Ther       Date:  1970-08

5.  Respiratory effects of butorphanol and pethidine.

Authors:  T Kallos; F S Caruso
Journal:  Anaesthesia       Date:  1979 Jul-Aug       Impact factor: 6.955

6.  Butorphanol and pentazocine in patients with severe postoperative pain.

Authors:  A B Dobkin; S Eamkaow; F S Caruso
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

7.  An oral buprenorphine and paracetamol combination compared with paracetamol alone: a single dose double-blind postoperative study.

Authors:  R E Bullingham; H J McQuay; R A Moore; L Weir
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

8.  Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts.

Authors:  J H Mendelson; J Ellingboe; N K Mello; J Kuehnle
Journal:  J Pharmacol Exp Ther       Date:  1982-02       Impact factor: 4.030

9.  Clinical effects of buprenorphine during and after operation.

Authors:  H J McQuay; R E Bullingham; G M Paterson; R A Moore
Journal:  Br J Anaesth       Date:  1980-10       Impact factor: 9.166

10.  Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs.

Authors:  M Pfeffer; R D Smyth; K A Pittman; P A Nardella
Journal:  J Pharm Sci       Date:  1980-07       Impact factor: 3.534
View more
  15 in total

1.  Preparation of biodegradable microspheres and matrix devices containing naltrexone.

Authors:  Rassoul Dinarvand; Shadi H Moghadam; Leyla Mohammadyari-Fard; Fatemeh Atyabi
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 3.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

4.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  The scientific basis of severe acute pain management in the emergency department.

Authors:  G D Phillips; C J Baggoley
Journal:  Arch Emerg Med       Date:  1986-03

Review 6.  Buprenorphine for neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Cathy Stannard; Dominic Aldington; Peter Cole; Roger Knaggs
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

Review 7.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

8.  Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Authors:  M A Huestis; E J Cone; S O Pirnay; A Umbricht; K L Preston
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

9.  Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.

Authors:  Mary F Divin; M C Holden Ko; John R Traynor
Journal:  Eur J Pharmacol       Date:  2008-01-24       Impact factor: 4.432

Review 10.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.